Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Hansa Biopharma AB (publ)    HNSA   SE0002148817

HANSA BIOPHARMA AB (PUBL)

(HNSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The tendency within the weekly time frame is positive above the technical support level at 133.6 SEK
Weaknesses
  • The company has insufficient levels of profitability.
  • The company's earnings releases usually do not meet expectations.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Most analysts recommend that the stock should be sold or reduced.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
HANSA BIOPHARMA AB (PUBL)-24.04%979
MODERNA, INC.27.29%52 622
LONZA GROUP AG4.64%49 880
CELLTRION, INC.-13.09%38 701
IQVIA HOLDINGS INC.4.76%35 985
SEAGEN INC.6.08%33 607
HANGZHOU TIGERMED CONSULTIN..8.93%23 361
INCYTE CORPORATION10.80%20 564
ALNYLAM PHARMACEUTICALS, IN..28.30%19 373
PHARMARON BEIJING CO., LTD.19.86%17 471
CHARLES RIVER LABORATORIES ..13.24%13 990
BIO-TECHNE CORPORATION12.01%13 733
CRISPR THERAPEUTICS AG20.89%13 682
PPD, INC.2.45%12 259
QIAGEN N.V.1.67%12 218
ICON PUBLIC LIMITED COMPANY11.77%11 501
More Results
Financials
Sales 2020 35,8 M 4,31 M 4,31 M
Net income 2020 -396 M -47,8 M -47,8 M
Net cash 2020 1 385 M 167 M 167 M
P/E ratio 2020 -19,4x
Yield 2020 -
Capitalization 8 121 M 979 M 980 M
EV / Sales 2020 188x
EV / Sales 2021 73,8x
Nbr of Employees 80
Free-Float 95,9%
Upcoming event on HANSA BIOPHARMA AB (PUBL)
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes